A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical benefit of the KIT inhibitor XL820 in
subjects with advanced gastrointestinal stromal tumors (GIST) who are resistant to or
intolerant of Imatinib and/or Sunitinib.